{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:09:04Z","timestamp":1782385744675,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12894-018-0393-9","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T11:39:27Z","timestamp":1537443567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion"],"prefix":"10.1186","volume":"18","author":[{"given":"Jean-Jacques","family":"Body","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"issue":"3","key":"393_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"393_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nrurol.2015.90","volume":"12","author":"JJ Body","year":"2015","unstructured":"Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol. 2015;12(6):340\u201356.","journal-title":"Nat Rev Urol"},{"issue":"9768","key":"393_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322.","journal-title":"Lancet"},{"issue":"11","key":"393_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879\u20132.","journal-title":"J Natl Cancer Inst"},{"key":"393_CR5","unstructured":"European Medicines Agency. Zometa\u00ae (zoledronic acid) Summary of Product Characteristics. 2016; Available at: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000336\/WC500051730.pdf\n                    \n                  . Accessed 27 Apr 2018."},{"key":"393_CR6","unstructured":"European Medicines Agency. XGEVA\u00ae (denosumab) Summary of Product Characteristics. 2018; Available at: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf\n                    \n                  . Accessed 6 Jun 2018."},{"key":"393_CR7","unstructured":"European Medicines Agency. Xgeva (denosumab) summary of opinion (post authorisation). 2018; Available at: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/002173\/WC500244274.pdf\n                    \n                  . Accessed 6 Jun 2018."},{"issue":"2","key":"393_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467\u201379.","journal-title":"Eur Urol"},{"key":"393_CR9","unstructured":"European Association of Urology. European Association of Urology guidelines \u2013 prostate cancer. 2018. Available at: \n                    http:\/\/uroweb.org\/guideline\/prostate-cancer\/#6\n                    \n                  . Accessed 27 Apr 2018."},{"issue":"16","key":"393_CR10","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392.","journal-title":"Eur J Cancer"},{"issue":"13","key":"393_CR11","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","volume":"51","author":"JJ Body","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damiao R, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015;51(13):1812\u201321.","journal-title":"Eur J Cancer"},{"issue":"3","key":"393_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11096-017-0455-1","volume":"39","author":"A Manzaneque","year":"2017","unstructured":"Manzaneque A, Chaguaceda C, Mensa M, Bastida C, Creus-Baro N. Use and safety of denosumab in cancer patients. Int J Clin Pharm. 2017;39(3):522\u20136.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"393_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1185\/03007995.2013.813840","volume":"29","author":"WX Qi","year":"2013","unstructured":"Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin. 2013;29(9):1067\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"393_CR14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00520-016-3543-1","volume":"25","author":"JJ Body","year":"2017","unstructured":"Body JJ, Niepel D, Tonini G. Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer. 2017;25(5):1639\u201349.","journal-title":"Support Care Cancer"},{"issue":"2","key":"393_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1022994104070","volume":"4","author":"JJ Body","year":"2003","unstructured":"Body JJ, Bouillon R. Emergencies of calcium homeostasis. Rev Endocr Metab Disord. 2003;4(2):167\u201375.","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"393_CR16","first-page":"158","volume":"58","author":"J Fong","year":"2012","unstructured":"Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician. 2012;58(2):158\u201362.","journal-title":"Can Fam Physician"},{"key":"393_CR17","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 2009; Available at: \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                  . Accessed 27 Apr 2018."},{"issue":"7656","key":"393_CR18","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1136\/bmj.39582.589433.BE","volume":"336","author":"MS Cooper","year":"2008","unstructured":"Cooper MS, Gittoes NJL. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298\u2013302.","journal-title":"BMJ"},{"issue":"6","key":"393_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0033-3182(99)71186-2","volume":"40","author":"PJ Velasco","year":"1999","unstructured":"Velasco PJ, Manshadi M, Breen K, Lippmann S. Psychiatric aspects of parathyroid disease. Psychosomatics. 1999;40(6):486\u201390.","journal-title":"Psychosomatics"},{"issue":"5","key":"393_CR20","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00520-016-3535-1","volume":"25","author":"T Tanaka","year":"2017","unstructured":"Tanaka T, Taguri M, Fumita S, Okamoto K, Matsuo Y, Hayashi H. Retrospective study of unplanned hospital admission for metastatic cancer patients visiting the emergency department. Support Care Cancer. 2017;25(5):1409\u201315.","journal-title":"Support Care Cancer"},{"issue":"11","key":"393_CR21","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"AL Huynh","year":"2016","unstructured":"Huynh AL, Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25(11):1274\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"393_CR22","unstructured":"Goltzman D. Approach to hypercalcaemia. 2016; Available at: \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279129\/\n                    \n                  . Accessed 27 Apr 2018."},{"issue":"2","key":"393_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.0954-6820.1986.tb02745.x","volume":"220","author":"CP Blomqvist","year":"1986","unstructured":"Blomqvist CP. A hospital survey of hypocalcemia in patients with malignant disease. Acta Med Scand. 1986;220(2):167\u201373.","journal-title":"Acta Med Scand"},{"issue":"3","key":"393_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/SPC.0b013e3283640f5f","volume":"7","author":"N Fallah-Rad","year":"2013","unstructured":"Fallah-Rad N, Morton AR. Managing hypercalcaemia and hypocalcaemia in cancer patients. Curr Opin Support Palliat Care. 2013;7(3):265\u201371.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"6","key":"393_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2796.1989.tb01423.x","volume":"226","author":"JA Riancho","year":"1989","unstructured":"Riancho JA, Arjona R, Valle R, Sanz J, Gonzalez-Macias J. The clinical spectrum of hypocalcaemia associated with bone metastases. J Intern Med. 1989;226(6):449\u201352.","journal-title":"J Intern Med"},{"issue":"12 Suppl","key":"393_CR26","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961\u201378.","journal-title":"Cancer"},{"issue":"2","key":"393_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1359\/jbmr.081112","volume":"24","author":"PJ Kostenuik","year":"2009","unstructured":"Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL. J Bone Miner Res. 2009;24(2):182\u201395.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"393_CR28","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00520-014-2142-2","volume":"22","author":"B Lechner","year":"2014","unstructured":"Lechner B, DeAngelis C, Jamal N, Emmenegger U, Pulenzas N, Giotis A, et al. The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Support Care Cancer. 2014;22(7):1765\u201371.","journal-title":"Support Care Cancer"},{"issue":"9","key":"393_CR29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1060028014539919","volume":"48","author":"H Ikesue","year":"2014","unstructured":"Ikesue H, Tsuji T, Hata K, Watanabe H, Mishima K, Uchida M, et al. Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Ann Pharmacother. 2014;48(9):1159\u201365.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"393_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/1078155216628325","volume":"23","author":"P Yerram","year":"2016","unstructured":"Yerram P, Kansagra S, Abdelghany O. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis. J Oncol Pharm Pract. 2016;23(3):179\u201384.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"393_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2478\/raon-2013-0041","volume":"47","author":"A Kmetec","year":"2013","unstructured":"Kmetec A, Hajdinjak T. Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid. Radiol Oncol. 2013;47(3):289\u201395.","journal-title":"Radiol Oncol"},{"issue":"3","key":"393_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.mehy.2011.12.002","volume":"78","author":"JW Ho","year":"2012","unstructured":"Ho JW. Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as a mechanism of hypocalcaemia. Med Hypotheses. 2012;78(3):377\u20139.","journal-title":"Med Hypotheses"},{"issue":"8","key":"393_CR33","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.2004.99.013","volume":"22","author":"TL Breen","year":"2004","unstructured":"Breen TL, Shane E. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol. 2004;22(8):1531\u20132.","journal-title":"J Clin Oncol"},{"key":"393_CR34","first-page":"565393","volume":"2014","author":"M Muqeet Adnan","year":"2014","unstructured":"Muqeet Adnan M, Bhutta U, Iqbal T, AbdulMujeeb S, Haragsim L, Amer S. Severe hypocalcemia due to denosumab in metastatic prostate cancer. Case Rep Nephrol. 2014;2014:565393.","journal-title":"Case Rep Nephrol"},{"issue":"10","key":"393_CR35","first-page":"607","volume":"14","author":"E Segal","year":"2012","unstructured":"Segal E, Felder S, Haim N, Yoffe-Sheinman H, Peer A, Wollner M, et al. Vitamin D deficiency in oncology patients--an ignored condition: impact on hypocalcemia and quality of life. Isr Med Assoc J. 2012;14(10):607\u201312.","journal-title":"Isr Med Assoc J"},{"issue":"21","key":"393_CR36","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jama.1995.03530210037027","volume":"274","author":"F Gloth","year":"1995","unstructured":"Gloth F, Gundberg CM, Hollis BW, Haddad JG, Tobin JD. Vitamin D deficiency in homebound elderly persons. JAMA. 1995;274(21):1683\u20136.","journal-title":"JAMA"},{"issue":"4","key":"393_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","volume":"72","author":"JP Droz","year":"2017","unstructured":"Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol. 2017;72(4):521\u201331.","journal-title":"Eur Urol"},{"issue":"9","key":"393_CR38","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-13-3085","volume":"20","author":"AB Murphy","year":"2014","unstructured":"Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CMP, Nadler RB, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res. 2014;20(9):2289\u201329.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"393_CR39","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/imj.13097","volume":"46","author":"JP Killen","year":"2016","unstructured":"Killen JP, Yong K, Luxton G, Endre Z. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease. Intern Med J. 2016;46(6):746\u20137.","journal-title":"Intern Med J"},{"issue":"4","key":"393_CR40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677\u201392.","journal-title":"Bone"},{"issue":"5","key":"393_CR41","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000368844","volume":"9","author":"C Domschke","year":"2014","unstructured":"Domschke C, Schuetz F. Side effects of bone-targeted therapies in advanced breast cancer. Breast Care. 2014;9(5):332\u20136.","journal-title":"Breast Care"},{"issue":"1","key":"393_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1):447\u201355.","journal-title":"Support Care Cancer"},{"key":"393_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.10.004","volume":"51","author":"JJ Body","year":"2016","unstructured":"Body JJ, Terpos E, Tombal B, Hadji P, Arif A, Young A, et al. Bone health in the elderly cancer patient: a SIOG position paper. Cancer Treat Rev. 2016;51:46\u201353.","journal-title":"Cancer Treat Rev"},{"key":"393_CR44","unstructured":"The British Dietetic Association. Food fact sheet: calcium. 2017; Available at: \n                    https:\/\/www.bda.uk.com\/foodfacts\/Calcium.pdf\n                    \n                  . Accessed 27 Apr 2018."},{"key":"393_CR45","unstructured":"National Institutes of Health. Calcium. 2016; Available at: \n                    https:\/\/ods.od.nih.gov\/factsheets\/Calcium-HealthProfessional\/#h5\n                    \n                  . Accessed 27 Apr 2018."},{"key":"393_CR46","unstructured":"British National Formulary. Calcium supplements. 2016. Available at: \n                    https:\/\/bnf.nice.org.uk\/treatment-summary\/minerals.html\n                    \n                  . Accessed 27 Apr 2018."},{"key":"393_CR47","doi-asserted-by":"publisher","first-page":"23229","DOI":"10.3402\/fnr.v58.23229","volume":"58","author":"H Wang","year":"2014","unstructured":"Wang H, Bua P, Capodice J. A comparative study of calcium absorption following a single serving administration of calcium carbonate powder versus calcium citrate tablets in healthy premenopausal women. Food Nutr Res. 2014;58:23229.","journal-title":"Food Nutr Res"},{"key":"393_CR48","doi-asserted-by":"publisher","DOI":"10.17226\/13050","volume-title":"Dietary reference intakes for calcium and vitamin D","author":"Institute of Medicine","year":"2011","unstructured":"Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011. \n                    https:\/\/doi.org\/10.17226\/13050"},{"issue":"3","key":"393_CR49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266\u201381.","journal-title":"N Engl J Med"},{"issue":"8","key":"393_CR50","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4065\/mcp.2010.0138","volume":"85","author":"KA Kennel","year":"2010","unstructured":"Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clinic Proc. 2010;85(8):752\u20138.","journal-title":"Mayo Clinic Proc"},{"key":"393_CR51","unstructured":"British Medical Journal. Best practice: vitamin D deficiency. 2017; Available at: \n                    http:\/\/bestpractice.bmj.com\/best-practice\/monograph\/641\/treatment\/step-by-step.html\n                    \n                  . Accessed 27 Apr 2018."},{"issue":"7","key":"393_CR52","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"393_CR53","unstructured":"International Osteoporosis Foundation. Vitamin D. Available at: \n                    https:\/\/www.iofbonehealth.org\/osteoporosis-musculoskeletal-disorders\/osteoporosis\/prevention\/vitamin-d\n                    \n                  . Accessed 27 Apr 2018."},{"key":"393_CR54","unstructured":"National Institute for Health and Care Excellence. Vitamin D deficiency in adults - treatment and prevention. 2016; Available at: \n                    https:\/\/cks.nice.org.uk\/vitamin-d-deficiency-in-adults-treatment-and-prevention#!topicsummary\n                    \n                  . Accessed 27 Apr 2018."},{"key":"393_CR55","unstructured":"British National Formulary. Vitamin D. 2016; Available at: \n                    https:\/\/bnf.nice.org.uk\/treatment-summary\/vitamins.html\n                    \n                  . Accessed 27 Apr 2018."},{"issue":"5","key":"393_CR56","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.bone.2009.07.015","volume":"45","author":"P Glendenning","year":"2009","unstructured":"Glendenning P, Chew GT, Seymour HM, Gillett MJ, Goldswain PR, Inderjeeth CA, et al. Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone. 2009;45(5):870\u20135.","journal-title":"Bone"},{"issue":"2","key":"393_CR57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/14712598.2012.756470","volume":"13","author":"C Buonerba","year":"2013","unstructured":"Buonerba C, Caraglia M, Malgieri S, Perri F, Bosso D, Federico P, et al. Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin Biol Ther. 2013;13(2):149\u201351.","journal-title":"Expert Opin Biol Ther"},{"key":"393_CR58","unstructured":"International Society of Nephrology. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). 2017. Available at: \n                    http:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/2017-KDIGO-CKD-MBD-GL-Update.pdf\n                    \n                  . Accessed 26 Apr 2018."},{"issue":"5","key":"393_CR59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10067-009-1328-3","volume":"29","author":"D den Uyl","year":"2010","unstructured":"den Uyl D, Geusens PP, van Berkum FN, Houben HH, Jebbink MC, Lems WF. Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clin Rheumatol. 2010;29(5):465\u201372.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"393_CR60","first-page":"e22","volume":"15","author":"SD Saini","year":"2009","unstructured":"Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22\u201333.","journal-title":"Am J Manag Care"},{"issue":"4","key":"393_CR61","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/joim.12394","volume":"278","author":"IR Reid","year":"2015","unstructured":"Reid IR, Bristow SM, Bolland MJ. Calcium supplements: benefits and risks. J Intern Med. 2015;278(4):354\u201368.","journal-title":"J Intern Med"},{"issue":"3","key":"393_CR62","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/jbmr.1484","volume":"27","author":"JR Lewis","year":"2012","unstructured":"Lewis JR, Zhu K, Prince RL. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J Bone Miner Res. 2012;27(3):719\u201322.","journal-title":"J Bone Miner Res"},{"key":"393_CR63","unstructured":"International Osteoporosis Foundation. Calcium content of common foods. 2017; Available at: \n                    https:\/\/www.iofbonehealth.org\/osteoporosis-musculoskeletal-disorders\/osteoporosis\/prevention\/calcium\/calcium-content-common-foods\n                    \n                  . Accessed 27 Apr 2018."},{"issue":"1","key":"393_CR64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10549-011-1415-4","volume":"127","author":"LJ Peppone","year":"2011","unstructured":"Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, et al. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat. 2011;127(1):171\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"9105","key":"393_CR65","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(05)78933-9","volume":"351","author":"A Malabanan","year":"1998","unstructured":"Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351(9105):805\u20136.","journal-title":"Lancet"},{"key":"393_CR66","first-page":"411","volume":"54","author":"R Singh","year":"2006","unstructured":"Singh R, Bhat MH, Bhansali A. Hypomagnesaemia masquerading as hypoparathyroidism. J Assoc Physicians India. 2006;54:411\u20132.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"393_CR67","doi-asserted-by":"publisher","first-page":"G9","DOI":"10.1530\/EC-16-0055","volume":"5","author":"J Walsh","year":"2016","unstructured":"Walsh J, Gittoes N, Selby P. Society for Endocrinology clinical C. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute hypercalcaemia in adult patients. Endocr Connect. 2016;5(5):G9\u2013G11.","journal-title":"Endocr Connect"},{"issue":"2","key":"393_CR68","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bone.2013.04.012","volume":"55","author":"F Milat","year":"2013","unstructured":"Milat F, Goh S, Gani LU, Suriadi C, Gillespie MT, Fuller PJ, et al. Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone. 2013;55(2):305\u20138.","journal-title":"Bone"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-018-0393-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T23:06:15Z","timestamp":1568934375000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-018-0393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1186\/s12894-018-0393-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"9 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J-JB has received speaker and consulting fees from Amgen. DN is an employee of Amgen and holds stocks. RvM has received research grants from Amgen and Bayer, has acted as a consultant for Amgen, Bayer, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme, Novartis, and Roche, and has received honoraria from Amgen, Bayer, and GlaxoSmithKline. BT is an advisor and an investigator for Amgen, Astellas, Janssen, Medivation, and Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"81"}}